Overview

Tocilizumab, Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery

Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Open heart surgery, including coronary artery bypass grafting (CABG) and/or aortic valve replacement (AVR) is associated with a significant risk of mortality. This study is a randomized clinical trial with the purpose of investigating five different interventions on the primary endpoint 'days alive and outside of hospital within 90 days'. The interventions are: - Tocilizumab vs. placebo administered after induction of anesthesia. - Dexamethasone vs. placebo administered after induction of anesthesia. - Olanzapine vs. placebo administered prior to anesthesia. - A blood-flow targeted vs. a blod-pressure targeted hemodynamic strategy while the patient is on cardio-pulmonary bypass (CPB) - Low-tidal volume ventilation vs. no ventilation of the lungs while the patient is on CPB
Phase:
N/A
Details
Lead Sponsor:
Rigshospitalet, Denmark
Treatments:
Dexamethasone
Dexamethasone 21-phosphate
Olanzapine